Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

BACKGROUND: Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in pre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Lau, Yvonne Y., Goldwasser, Meredith, Boral, Anthony L., Engelman, Jeffrey A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4079055/
https://ncbi.nlm.nih.gov/pubmed/24670165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1311107
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares